Bản dịch chưa sẵn sàng. Đang hiển thị bài viết gốc.
Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. "The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results. For example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.